about
Risk factors and short-term projections for serotype-1 poliomyelitis incidence in Pakistan: A spatiotemporal analysis.Polio elimination in Nigeria: A reviewPolio vaccination: past, present and future.Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia.Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infantsInactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.Heavy alcohol use as a risk factor for severe outcomes among adults hospitalized with laboratory-confirmed influenza, 2005-2012.New poliovirus vaccine schedules - Authors' reply.Population Migration Through Railroads And Spatial Diffusion Of Polio In India: A Cross-Sectional PrQuantitative multiplex one-step RT-PCR assay for identification and quantitation of Sabin strains of poliovirus in clinical and environmental specimensEvaluation of the bag-mediated filtration system as a novel tool for poliovirus environmental surveillance: Results from a comparative field study in Pakistan.Evolving epidemiology of poliovirus serotype 2 following withdrawal of the type 2 oral poliovirus vaccineImmunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of ageImmunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, following vaccination in children at 2, 4, 6 and at 15-18 months
P50
Q33788109-C8DDB85F-0C4F-4451-A75B-CB8D4E11C6F5Q37135154-03B58C7C-C3E3-4B2B-AC19-86842E8D21D1Q38396773-D8A0DBA6-9E2E-4CB2-A587-2C6A35CCE5D7Q38846556-5F9A6DB4-538B-4996-8A2E-67628564D324Q40537256-DD43BA9B-5CDA-46D0-B099-9DEF0718B1A6Q40595130-3BEC0CE3-6445-4394-9D89-4E1EECDBDED2Q40664092-3D47877B-6592-44CA-ABC0-797E54B2ACADQ42240349-9A8FAA6E-7A83-49C7-BA58-ADEEAB299CDCQ54482743-8304F42B-0F4E-4E19-B78E-BF2C0DBC0195Q56777414-9EB1C888-5F18-4BC5-B2DA-771BEB1EB9F8Q59358489-FB9D5703-3C0C-4CFD-AF00-522A7CA0FD9CQ64907094-F017D972-6EE6-4C01-8D06-0D2B57458F00Q90470469-BECDB225-01A7-45EC-84B1-C3B0FFB04F54Q91193618-77EAF3C5-D69C-45A6-BFB9-239ED49A898DQ91784566-04459D47-CBA2-4F16-BB24-70A3491D249B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ananda S Bandyopadhyay
@nl
Ananda S Bandyopadhyay
@sl
Ananda S. Bandyopadhyay
@en
Ananda S. Bandyopadhyay
@es
type
label
Ananda S Bandyopadhyay
@nl
Ananda S Bandyopadhyay
@sl
Ananda S. Bandyopadhyay
@en
Ananda S. Bandyopadhyay
@es
prefLabel
Ananda S Bandyopadhyay
@nl
Ananda S Bandyopadhyay
@sl
Ananda S. Bandyopadhyay
@en
Ananda S. Bandyopadhyay
@es
P106
P1153
55922677400
P31
P496
0000-0002-8395-2001